{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-167893","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.635782+00:00","generated_at":"2026-06-14T00:27:34.282192+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"ORIC Pharmaceuticals annual meeting elects directors, ratifies KPMG as auditor","bullets":["81.9% of outstanding shares represented at June 14, 2023 annual meeting.","Jacob M. Chacko, M.D. elected with 31,394,488 votes for, 576,707 withheld.","Mardi C. Dier elected with 25,659,351 votes for, 6,311,844 withheld.","KPMG LLP ratified as independent auditor for FY2023: 36,376,853 for, 1,701 against, 553,159 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-167893","json":"https://secwatch.observer/filing/0001193125-23-167893.json","markdown":"https://secwatch.observer/filing/0001193125-23-167893.md","text":"https://secwatch.observer/filing/0001193125-23-167893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523167893/0001193125-23-167893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523167893/d491519d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:27:34.282192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91d84d516c49d088b58bb82682db99e1ea5092bb","claim":"Oric Pharmaceuticals, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm at the 2023-06-14 meeting.","evidence_excerpt":"The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523167893/0001193125-23-167893-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"ad909410cb07fe607b1de21b71d65afedf24e27b","claim":"Oric Pharmaceuticals, Inc. shareholders approved Election of Class III directors at the 2023-06-14 meeting.","evidence_excerpt":"Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523167893/0001193125-23-167893-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}